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MaAging is the main risk factor for vascular disease and ensuing cardiovascular and cerebrovascular events, the leading
causes of death worldwide. In a progressively aging population, it is essential to develop early-life biomarkers that
efficiently identify individuals who are at high risk of developing accelerated vascular damage, with the ultimate goal of
improving primary prevention and reducing the health care and socioeconomic impact of age-related cardiovascular
disease. Studies in experimental models and humans have identified 9 highly interconnected hallmark processes driving
mammalian aging. However, strategies to extend health span and life span require understanding of interindividual
differences in age-dependent functional decline, known as biological aging. This review summarizes the
current knowledge on biological age biomarkers, factors influencing biological aging, and antiaging interventions, with a
focus on vascular aspects of the aging process and its cardiovascular disease related manifestations.(J Am Coll Cardiol 2020;75:919–30) © 2020 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).A ging is the main risk factor for vascular dis-ease and the ensuing cardiovascular and ce-rebrovascular events, which are the leading
causes of death worldwide (1). Vascular aging entails
arterial degeneration and hardening that impairs
vascular function and ultimately causes end organ
damage, predominantly in the heart, brain, and kid-
ney. Age-dependent arterial injury typically mani-
fests clinically after the fifth or sixth decade of life;
however, there is a high interindividual variability
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HIGHLIGHTS
 Vascular disease onset and mortality are
highly variable among individuals.
 Chronological age is suboptimal for esti-
mating vascular aging.
 Biological vascular age should be used to
select individuals for early prevention of
cardiovascular disease.
 Biological vascular aging can be targeted
by behavioral and pharmacological
interventions.





CACS = coronary artery
calcium score
CAD = coronary artery disease
CVD = cardiovascular disease
DNAmAge = DNA methylation
age
IMT = intima-media thickness
mTOR = mechanistic target of
rapamycin
PWV = pulse wave velocity
T2D = type 2 diabetes
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Biomarkers that truly reflect the state of
vascular aging are needed to improve early
detection of individuals at high risk of
developing cardiovascular disease (CVD).
Ideal biological age biomarkers should
outperform chronological age as de-
terminants of morbidity and mortality.
Moreover, their quantification should be easy
and safe, preferably in a blood test or by a
noninvasive imaging technique (4). Biolog-
ical age indicators described to date vary
from phenotypic and functional scores to
molecular biomarkers. This section discusses
molecular and cellular biomarkers that reflectthe decline in function of all tissues including the
vasculature, functional, and structural indicators of
biological vascular age and composite biomarker
predictors of biological age (Figure 2).
MOLECULAR AND CELLULAR BIOMARKERS. Aging
can be defined at the molecular and cellular level by
the presence of 9 hallmarks (5), some of which, such
as telomere attrition and epigenetic alterations, are
commonly used to assess human biological age.
Telomeres consist of repetitive DNA sequences bound
by specific nucleoproteins that protect chromosome
ends (6). Telomeres shorten with each cell division,
and this attrition can cause cell senescence when
telomeres shorten beyond a critical length (6). Age-
dependent telomere shortening is associated with
coronary artery disease (CAD) and predicts both all-
cause and CVD-related mortality; however, it re-
mains uncertain whether telomere attrition promotes
CVD (4,6,7).
DNA methylation is a major epigenetic mechanism
regulating gene expression. Various studies have
identified specific CpG sites undergoing age-related
changes in methylation (8,9). Hannum et al. (10)
and Horvath (11) described 2 widely used DNA
methylation age predictors (DNAmAges, also called
epigenetic clocks) based on 71 and 353 CpGs, respec-
tively. DNAmAge seems to be a good predictor of all-
cause and CVD mortality and, to a lesser extent,
incident CVD (12,13).
During aging, somatic cells accumulate mutations
in their DNA, and these mutations can provide a
competitive advantage, particularly to highly prolif-
erative cells, thus leading to expansion of mutant
clones and mosaicism (14). Somatic mutation–relatedexpansion of hematopoietic cells (clonal hematopoi-
esis) has typically been linked to cancer; however,
recent findings demonstrated an association with
increased CVD risk suggesting a potential role as a
major driver of atherosclerosis, thus identifying
clonal hematopoiesis as a possible novel biomarker of
vascular aging (14).
Another characteristic of aging is chronic low-grade
inflammation (inflammaging), which can be assessed
by measuring circulating levels of proinflammatory
molecules, such as elevated C-reactive protein and
interleukin 6 (15). Inflammaging, a risk factor for many
chronic diseases, including CVD, is partially driven by
increased gut permeability and altered microbiota
composition. Gut dysbiosis also has the potential to
become a biological age estimator because it has been
linked to longevity and disease (16).
Aging affects the levels of proteins, metabolites,
and other biomolecules in body fluids. Higher
morbidity and mortality rates have been linked to
changes in individual molecules, such as insulin-like
growth factor-1, growth hormone, and low-density
lipoproteins (17,18). Because single molecule bio-
markers tend to be oversimplistic, various high-
throughput approaches have been used to analyze
age-related changes in the transcriptome, proteome,
and metabolome to search for a more comprehensive
omics-based “blueprint” of aging, such as GlycanAge
(GlycanAge Ltd., London, United Kingdom) or Meta-
bolic Age scores (4).
VASCULAR FUNCTIONAL AND STRUCTURAL
BIOMARKERS. Structural changes in aging arteries
include elastin fragmentation, collagen accumula-
tion, and medial vascular smooth muscle cell loss,
causing reduced vascular compliance and increased
arterial stiffness (19). The most common arterial
stiffness measure is pulse wave velocity (PWV), the
velocity at which the blood pressure wave moves
along the arterial tree. Carotid to femoral PWV is the




Individuals with unhealthy lifestyle and/or
family history of cardiovascular disease
Patients with type 2 diabetes, chronic kidney
disease, autoimmune diseases, human
immunodeficiency virus infection
Patients with genetic diseases (familial
























Biological aging refers to the decline in tissue/organismal function, whereas chronological aging simply indicates the time passed since birth.
In normally aging individuals, chronological age equates to biological age. Vascular aging is delayed in centenarians and supercentenarians
and is accelerated in certain diseases and conditions.
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921most extensively validated and standardized mea-
sure; however, brachial-ankle and heart-ankle PVW
are also popular in the clinic (20,21). PWV correlates
with chronological age, and a high PWV increases the
risk of CVD and all-cause mortality (22,23). Arterial
stiffening typically precedes and promotes hyper-
tension, but hypertension can also accelerate arterial
stiffening, indicating the existence of a positive
feedback loop (24). Blood pressure also increases
during aging and is associated with cardiovascular
events and mortality (25).
Another common feature of vascular aging is
atherosclerosis, which consists of lipid-rich plaque
buildup in the intima that can lead to acute myocar-
dial infarction or stroke. Endothelial dysfunction, a
major driver of atherogenesis, can be measured by
ultrasound as flow-mediated dilation (26), and flow-
mediated dilation decreases during aging and is an
independent predictor of CVD outcomes (26,27).
Vascular ultrasound is also frequently used to mea-
sure intima-media thickness (IMT) as an estimate of
subclinical atherosclerosis burden in large arteries
(28,29). Carotid IMT increases with age (30) and is
associated with both the prevalence and the inci-
dence of CVD morbidity and mortality (31). However,
increased IMT can also reflect nonatherosclerotic
processes (30,32). More advanced atherosclerosisstages can be evaluated by quantifying various ca-
rotid plaque parameters, such as plaque presence,
number, thickness, area, and volume (33), which
outperform carotid IMT as a predictor of future CAD
events (32).
Vascular aging is also characterized by the depo-
sition of calcium phosphate crystals in both the
arterial intima (typically related to atherosclerosis)
and the media (called Mönckeberg sclerosis) (34).
Both types of calcification often develop in parallel
and are not always easily distinguished by imaging
techniques (35). Computed tomography is the gold
standard technique for quantification of coronary
artery calcium score (CACS) (36). Even though CACS
can be influenced by the presence of medial calcifi-
cation, it is typically used as a surrogate marker for
the extent of atherosclerosis because it correlates
well with coronary plaque burden (37). CACS corre-
lates with chronological age (38) and is a powerful
predictor of incident CVD and all-cause mortality
(39–41). An arterial age calculator based on CACS (40)
is freely available online (42).
COMPOSITE BIOMARKER PREDICTORS. Age estima-
tion based on 1 of the previously mentioned bio-
markers often fails to reflect the complexity of aging
and can give suboptimal assessments of biological
FIGURE 2 Biomarkers of Biological Vascular Aging
Noninvasive
techniques
• Arterial stiffness (e.g., carotid-to-
  femoral pulse wave velocity)
• Blood pressure
• Endothelial dysfunction (e.g., flow-
  mediated dilation)
• Intimal thickening (e.g., carotid
  intima-media thickness)
• Atherosclerosis (e.g., total plaque
  burden)
• Calcification (e.g., coronary artery
  calcium score)
Functional and structural
• Telomere length
• DNAmAge (e.g., Hannum and
  Horvath epigenetic clocks)
• Somatic mutations
• Inflammaging markers (e.g.,
  interleukin 6, C-reactive protein)
• Insulin-like growth factor 1,







• Vascular Aging Index
• Frailty indices (e.g., Frailty index 34)
• Klemera–Doubal Method Biological Age
Composite biomarker predictors
Biomarkers of biological vascular aging
The biological age of the vasculature can be estimated using molecular and cellular biomarkers (in blood, urine, or feces), functional and structural vascular parameters
(measured by noninvasive techniques), or a combination of both. This figure was created with images modified from Servier Medical Art by Servier licensed under a
Creative Commons Attribution 3.0 Unsupported License. DNAmAge ¼ DNA methylation age.
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from compound scores. Composite biomarkers vary
from combinations of a few biomarkers to highly
complex scores developed using machine learning/
artificial intelligence tools that cover multiple aspects
of aging. For instance, CVD prediction is improved by
the integration of carotid IMT with aortic PWV into
the Vascular Aging Index (43). Likewise, Frailty Index
34, composed of 34 measures of health and function
in diverse body systems, including the vasculature,
outperforms DNAmAge at predicting mortality (44).
Many other biological age estimators were developed
by combining physical, physiological, and biochem-
ical parameters; for example, the Klemera-Doubal
Method Biological Age index is based on 10 bio-
markers (45,46). However, as composite predictors of
biological age become more complex, they often
become impractical and costly and therefore more
difficult to apply to the entire population.FACTORS INFLUENCING BIOLOGICAL AGING
OF THE VASCULAR SYSTEM
To identify factors that control biological aging,
multiple studies have compared individuals with
early and late onset of aging symptoms. Findings in
castrated males and postmenopausal women have
provided insight into the role of sex hormones in the
aging process. Similarly, studies of identical twins
have allowed the contribution of nonmodifiable ge-
netic features to longevity and disease to be studied
separately from the influence of environmental and
lifestyle factors. Hints about longevity-promoting
factors have also been obtained from research on
“Blue Zones,” geographic regions with an above
average proportion of centenarians. Nutritional clues
to healthy aging have been derived from a compari-
son of healthy and unhealthy diets. Additional insight
into aging has come from research into conditions
FIGURE 3 Factors Influencing Biological Vascular Age
• Obesity [↑]
• Type 2 diabetes [↑]
• Chronic kidney disease [↑]
• Autoimmune diseases (e.g.,
  rheumatoid arthritis and
  systemic lupus
  erythematosus) [↑]
• Patients treated for HIV [↑]
• Familial dyslipidemias [↑]
• Inherited arterial calcification
  syndromes [↑]
• Premature aging syndromes
  (e.g., Werner syndrome and
  Hutchinson-Gilford progeria
  syndrome) [↑]
• High meat and saturated fat
  intake [↑]
• High salt intake [↑]
• High refined sugar intake [↑]
• Smoking [↑]
• Alcohol abuse [↑]
• Drug abuse [↑]
• Physical activity [↓]
• Healthy sleeping habits [↓]
• High fruit and vegetable
  consumption [↓]
• Nuts, seeds and legumes
  consumption [↓]
• Moderate alcohol







• Air pollution [↑]
• Unhealthy parental lifestyle
  during pregnancy [↑]
• Family history of
  cardiovascular disease [↑]
• Exceptional parental
  longevity [↓]
• Low socioeconomic status [↑]
• Male sex [↑]
• Female sex, especially
  before menopause [↓]
Psychological factors
• Chronic stress [↑]
[Y] ¼ factors decelerating biological aging; [[] ¼ factors accelerating biological aging; HIV ¼ human immunodeficiency virus.
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923and diseases featuring a premature onset of aging.
This section discusses key nonmodifiable and modi-
fiable factors that influence vascular health and
longevity as well as examples of diseases and condi-
tions featuring early vascular impairment (Figure 3).
SEX AND INHERITABLE FACTORS. Women have a
higher life expectancy than men, and a large majority
of centenarians are women (47). Moreover, the risk of
CAD is higher in men, especially below the age of 50.
Accordingly, women have longer telomeres (4), lower
DNAmAges (4,10,12), and lower CACSs (38) than age-
matched men. This sex-dependent effect can be
partially attributed to the vasculoprotective role of
estrogen (47). There is also a possible adverse impact
of testosterone on aging because eunuchs were re-
ported to live longer than noncastrated men of the
same socioeconomic status (48). Yet, the impact of
testosterone on cardiovascular health remains
controversial (49).
Health span and longevity are also crucially influ-
enced by inheritable factors, mostly genetic and
epigenetic. For example, family CVD history increases
future CVD risk from 40% to 75% depending on the
degree of relatedness (50). Moreover, many geneticvariants are associated with an exceptionally long life
span (51), and offspring of centenarians show signs of
low epigenetic age in blood cells (52). There are also
ethnic differences in various measures of biological
age and CVD morbidity and mortality (38,53). Never-
theless, a meta-analysis of twin studies revealed that
genetics accounts for only 20% to 30% of the life span
variation (54), indicating that aging and longevity are
significantly modulated by other factors, such as
environment and lifestyle.
ENVIRONMENT AND LIFESTYLE. The influence of the
environment on vascular aging begins before birth
through in utero (developmental) programming (55).
Parental lifestyle during pregnancy can elicit adverse
effects on the long-term health of the offspring (56).
Autopsy studies have detected atherosclerotic lesions
in arteries of fetuses and neonates of smoker or hy-
percholesterolemic mothers (57,58), possibly reflect-
ing epigenetic alterations (59). During postnatal life,
the pace of biological aging can be affected by a wide
range of environmental and lifestyle factors. Physical
inactivity is a major mortality risk factor, and even
small amounts of exercise reduce CVD and all-cause
mortality (60,61). Another key modulator of vascular
CENTRAL ILLUSTRATION Strategies to Decelerate Biological Aging of the Vascular System
Hamczyk, M.R. et al. J Am Coll Cardiol. 2020;75(8):919–30.
See Table 1 for details. NADþ ¼ nicotinamide adenine dinucleotide.
Hamczyk et al. J A C C V O L . 7 5 , N O . 8 , 2 0 2 0
Biological Versus Chronological Vascular Aging M A R C H 3 , 2 0 2 0 : 9 1 9 – 3 0
924function and CVD risk is diet, with healthy aging
linked to unprocessed, plant-based nutrition with
moderate consumption of lean meat and fish, features
of the Mediterranean and Dietary Approaches to Stop
Hypertension diets (62,63). The key components of
Western-type diets that promote atherosclerosis and
hypertension are refined sugars, processed meat,
hydrogenated vegetable oils, and high amounts of
salt (62,63). Apart from the types of food consumed,
the quantity of ingested food plays a crucial role in
aging, with overeating increasing the risk of obesity,
CVD, and death. Notably, the exceptional longevity of
Japanese people living on Okinawa island, a Blue
Zone, was partially attributed to mild and constant
reduction in calorie intake (64). Smoking, drugs, and
alcohol abuse are unequivocally linked to accelerated
vascular aging and shorter life expectancy (62,65,66).
Nonetheless, moderate alcohol consumption corre-
lates with a lower incidence of CAD and has some
cardiometabolic benefits (62). Other factors influ-
encing aging and longevity are air quality, sleepduration and quality, psychological factors, and so-
cioeconomic status (67–71).
DISEASE AND CONDITIONS. Multiple inheritable
and acquired conditions and diseases can accelerate
vascular aging and lead to an early death. Acquired
conditions are frequently caused by an unhealthy
lifestyle and are highly interconnected. For instance,
obesity is associated with reduced life expectancy, in
part due to increased cardiovascular mortality (72).
Obesity and fat distribution influence many vascular
age measures, including arterial stiffness, carotid
IMT, and inflammation markers. Obesity is also a risk
factor for type 2 diabetes (T2D), a metabolic disorder
featuring hyperglycemia, insulin resistance, and
increased CVD-dependent mortality. Moreover, T2D
is a common cause of chronic kidney disease, which is
characterized by extensive vascular calcification and
increased CVD-related mortality (73).
Atherosclerosis is accelerated by autoimmune dis-
eases, such as systemic lupus erythematosus and
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925rheumatoid arthritis, in accordance with the central
role of inflammation in aging and associated vascular
disease (74). Furthermore, premature vascular aging
is a common presentation in individuals infected with
human immunodeficiency virus, in part due to the
side effects of antiretroviral drugs (75).
An early onset of vascular aging is a feature of
multiple genetic diseases. Familial dyslipidemias,
such as familial hypercholesterolemia, are a group of
genetic diseases that alter lipid metabolism and
require pharmacological treatment to prevent early-
onset atherosclerosis (76). Generalized arterial calci-
fication of infancy and pseudoxanthoma elasticum
are inherited syndromes associated with defective
extracellular pyrophosphate metabolism and arterial
calcification (77). Generalized arterial calcification of
infancy begins in utero and causes severe calcific
stenosis, hypertension, heart failure, and death
within the first 6 months of life. Pseudoxanthoma
elasticum has a milder course and features CVD.
Hutchinson-Gilford progeria syndrome is caused by
mutations in the LMNA gene and features most
vascular alterations found in the elderly, such as
atherosclerosis, arterial stiffness, and calcification.
These defects lead to death in the second decade of
life, typically from myocardial infarction or stroke (1).
Patients with Werner syndrome carrying mutations in
the WRN gene develop age-related diseases,
including T2D, atherosclerosis, myocardial infarction,
and cancer, and die at an average age of 54 years (78).
STRATEGIES TO DECELERATE
VASCULAR AGING
Studies of factors and diseases that accelerate and
decelerate biological aging have identified multiple
mechanisms that control this process. This section
summarizes key behavioral and pharmacological in-
terventions targeting these processes with the po-
tential to promote vascular health and longevity
(Central Illustration, Table 1).
BEHAVIORAL STRATEGIES. Aside from the obvious
measures of avoiding or quitting smoking and
avoiding excessive alcohol consumption, several
other interventions can reduce both global and
vascular biological aging. One of the most prominent
measures is physical activity, especially aerobic ex-
ercise, which is linked to a reduced incidence of age-
related diseases, decreased vascular and molecular
measures of biological age and CVD risk factors, and
an extended life span in humans (60,61,79–82).
Caloric restriction and fasting are the best docu-
mented strategies to prolong the life span across
several model species (81). Even without increasingphysical activity, reducing energy intake in obese
humans improves endothelial function and reduces
arterial stiffness and blood pressure, partially due to
weight and fat mass loss (82,83). Likewise, 2-year
follow-up in the CALERIE (Comprehensive Assess-
ment of Long-term Effects of Reducing Intake of En-
ergy) clinical trial showed reductions in CVD risk (84),
inflammation (64), and biological age in nonobese
subjects (85). Nevertheless, sustained calorie restric-
tion can lead to the loss of lean muscle mass and bone
density (82), and its long-term effects on survival in
nonobese humans remain unknown.
Changes in dietary composition can also have a
strong modulatory effect on aging and vascular dis-
ease. For example, the Mediterranean and Dietary
Approaches to Stop Hypertension diets reduce long-
term weight gain and are associated with a lower
risk of adverse clinical events (62). Likewise, high
vegetable and fruit intake is associated with
improved endothelial function and decreased arterial
stiffness and blood pressure (63,82). Arterial function
can be improved and CVD risk reduced by the con-
sumption of cocoa, tea, coffee, fermented dairy
products, fish, nuts, seeds, whole grains, legumes,
and olive oil (63). Furthermore, dietary sodium re-
striction lowers blood pressure and reduces arterial
stiffness (82).
PHARMACOLOGICAL STRATEGIES. Despite the un-
questionable beneficial effects of behavioral strate-
gies on heath span and life span, long-term adherence
to these habits is typically low. Thus, pharmacological
targeting of pathways that are modified by behavioral
approaches presents a more practical alternative. Key
signaling cascades regulated by caloric restriction are
the energy- and nutrient-sensing pathways, including
the mechanistic target of rapamycin (mTOR), adeno-
sine monophosphate–activated protein kinase
(AMPK), and sirtuin pathways (5). Aging dysregulates
these pathways, and their pharmacological modula-
tion extends life span in various species, including
mammals (86,87).
Rapamycin, an inhibitor of mTOR that also acti-
vates AMPK, is typically used as an immunosup-
pressant in organ transplant recipients and as an
antiproliferative agent in the treatment of some can-
cers. Compared with other immunosuppressants,
rapamycin diminishes arterial stiffness, blood pres-
sure, and carotid IMT in kidney transplant recipients,
suggestive of its vasculoprotective properties
(88–90). Furthermore, rapamycin and its analogues
(rapalogs) show antiatherosclerotic properties in
preclinical models and are used clinically to prevent
in-stent restenosis and cardiac allograft vasculopathy
(91,92). Nevertheless, the use of rapamycin to
TABLE 1 Behavioral and Pharmacological Strategies to Decelerate Biological Aging of the Vascular System
Strategy
Intervention
or Treatment Beneficial Effects Side Effects Ref. #
Behavioral
Physical activity Reduced CVD risk and mortality
Loss of abdominal fat and reduction of waist/hip ratio
Improved measures of vascular health (endothelial
function, arterial stiffness, and blood pressure)
Favorable outcomes in the lipid profile
Reduced inflammation markers
Increased insulin sensitivity
Excessive exercise in the elderly may
increase mortality risk
Excessive endurance exercise may have
adverse effects on cardiac structure
and function
(60,81,82,103–105)
Caloric restriction Reduced CVD risk
Weight and fat mass loss
Improved measures of vascular health
(endothelial function, arterial stiffness, blood
pressure, and carotid intima-media thickness)
Reduced cholesterol and TG
Reduced inflammation markers
Increased insulin sensitivity
May produce loss of bone density and
lean muscle mass




Reduced weight, waist circumference, and
abdominal fat
Reduced blood pressure
Decreased glucose, total cholesterol, LDL, and TG
Reduced inflammation markers
Increased insulin sensitivity
Fatigue, weakness, and headaches
Might be harmful to children, under
weight people, the elderly, and type 1




Reduced CVD risk and mortality
Reduced long-term weight gain
Improved measures of vascular health (endothelial
function, arterial stiffness, and blood pressure)
Favorable outcomes in the lipid profile
Reduced inflammation markers
Positive effects on gut microbiota composition
and diversity
(62,82,110,111)
Low sodium intake Improved measures of vascular health
(endothelial function, arterial stiffness,
blood pressure)
Lower risk of cardiovascular events (?)*
Possible negative impact on lipid profile
Increased renin, aldosterone,
noradrenaline, and adrenaline
Orthostatic complaints (in chronic kidney
disease patients)
(62,63,82,112,113)
Continued on the next page
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926promote healthy vascular aging is limited by adverse
side effects, including hyperglycemia, hyperlipid-
emia, and insulin resistance (93). Ongoing research is
testing several rapalogs in the search for a safer
alternative, and some beneficial effects have been
reported, including enhanced immune function and
reduced infections in the elderly (94).
Metformin is the most prescribed drug for T2D and
shows very mild side effects (87). Apart from
increasing insulin sensitivity, metformin targets a
series of age-related mechanisms, including AMPK
activation and mTOR inhibition. Metformin treat-
ment reduces vascular age measures, including arte-
rial stiffness, endothelial dysfunction, and CACS
(95,96) and decreases CVD risk and mortality (87).
Resveratrol is a polyphenol naturally present in red
wine, grapes, and other berries. It activates sirtuin-1
and AMPK and inhibits the mTOR pathway (97).Resveratrol has shown vasculoprotective effects in
preclinical models, and clinical trials have demon-
strated moderately diminished systolic blood pres-
sure in hypertensive patients and glycemia in T2D
patients; however, some undesirable side effects
have been reported, such as possibly blunting the
benefits of exercise in the elderly (98). Nicotinamide
adenine dinucleotide precursors, such as nicotin-
amide riboside and nicotinamide mononucleotide,
are another group of sirtuin activators that ameliorate
vascular aging in mice (99). Preliminary studies in
humans suggested their potential use to reduce
arterial stiffness and blood pressure (100), and a
clinical trial was launched in 2019 (101).
Strategies targeting inflammation are emerging as
potential therapies to counteract vascular aging (82).
Blockade of tumor necrosis factor-a reduced arterial








Reduced in-stent restenosis and associated risk of
major adverse cardiac events
Delayed progression of cardiac allograft
vasculopathy
Diminished arterial stiffness, blood pressure, and
carotid intima-media thickness (compared with











Metformin Reduced CVD risk and mortality
Weight and fat mass loss
Improved measures of vascular health (arterial
stiffness, blood pressure, coronary artery calcium
score, and carotid intima-media thickness)




Minor gastrointestinal side effects
Hypoglycemia (when used with
antidiabetes drugs or insulin)




Resveratrol Weight loss and reduced waist circumference
and fat mass
Improved cerebral blood flow
Reduced blood pressure (?)
Decreased plasma glucose, TG, and total
cholesterol (?)
Decreased inflammation markers (?)
Mild to moderate gastrointestinal symptoms
(at high doses)
May counteract the cardioprotective effects
of exercise
(98,119,120)
NADþ precursors Decreased blood pressure and arterial stiffness
Decreased TG and LDL and increased HDL
Painful flushes (at high doses) (82,121)
Antiproinflammatory
cytokine therapies
Reduced risk of recurrent CVD events
Reduced arterial stiffness and carotid intima-media
thickness
Increased incidence of fatal infections (82,102)
*Dependent on the degree of sodium restriction.
(?) ¼ inconsistent results between studies; CVD ¼ cardiovascular disease; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; NADþ ¼ nicotinamide adenine dinucleotide; TG ¼ triglyceride.
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927patients, and inhibition of interleukin-1b diminished
the risk of recurrent CVD events in individuals with
previous myocardial infarction and elevated C-reac-
tive protein (82,102). However, the use of antiproin-
flammatory therapies in heathy subjects is limited by
the increased risk of fatal infections.
Because gut dysbiosis contributes to inflammaging,
the administration of prebiotics and probiotics might
provide additional health benefits (15). Furthermore,
a series of medications widely prescribed for chronic
age–related vascular disease, such as aspirin, statins,
and antihypertensive drugs, might also be considered
antiaging pharmaceuticals. However, these com-
pounds are not currently prescribed to healthy
individuals.
CONCLUSIONS AND PERSPECTIVES
Age-related vascular damage does not only depend
on heritable traits but also can be influenced by life-
style, environment, and accompanying diseases.Therefore, assessments of vascular disease risk to
make recommendations for early prevention should
be based not on chronological age but rather on bio-
logical age. Although multiple biological age bio-
markers have been described, the correlation among
them is lower than expected (46), suggesting that
some estimates of biological age may reflect different
aspects of the aging process. Therefore, more
research is needed to validate and refine existing
aging biomarkers and to identify more accurate and
robust aging indicators. Based on the identification of
factors and diseases that change the pace of aging,
various antiaging strategies have been proposed to
promote healthy aging and postpone the appearance
of age-related vascular disease. At present, behavioral
antiaging approaches are the most promising; how-
ever, they present serious challenges due to limited
adherence of individuals to regular exercise, long-
term dietary recommendations, and other lifelong
lifestyle changes. On the other hand, the use of
pharmacological approaches to delay aging in healthy
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928individuals is still controversial due to their potential
long-term side effects, which may exceed the bene-
fits. However, what is clear is that antiaging in-
terventions should focus on extending the health
span rather than simply prolonging life span. Strate-
gies to promote healthy aging will not only benefit the
individual but also reduce the medical, economic,
and sociological impact associated with the progres-
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